CRISPR Therapeutics CRSP is expected to report fourth-quarter and full-year 2024 earnings later this month. The Zacks ...

We expect the company to start recording collaboration revenues ... of CRISPR Therapeutics have lost nearly 34% in the past year compared with the industry’s 14% decline, as seen in the chart ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

CRISPR Therapeutics AG (NASDAQ ... While recent revenue growth reached 19.31%, analysts anticipate a sales decline in the current year, highlighting the importance of monitoring the company's ...

CRISPR Therapeutics' stock ... approved by the FDA for a year now. Yet as of the latest reporting period ended September 30, 2024, it has not yet realized revenue from this treatment.

EST Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics (CRSP) todayMaximize Your Portfolio with Data Driven ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared ... the company is yet to record revenues from its sales. Also, a lack of pipeline updates ...

CRISPR Therapeutics stands at a critical juncture in its development, with the commercial launch of Casgevy and a pipeline rich with potential. While recent revenue growth reached 19.31%, analysts ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset ... the company is yet to record revenues from its sales. Also, a lack of pipeline ...